These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 660755)

  • 1. Renal cell carcinoma: natural history and results of treatment.
    Patel NP; Lavengood RW
    J Urol; 1978 Jun; 119(6):722-6. PubMed ID: 660755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural history of renal cell carcinoma.
    Paulson DF
    Semin Urol Oncol; 1996 Nov; 14(4):203-7. PubMed ID: 8946618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spontaneous rupture of a hybrid oncocytic chromophobe tumor: A case report.
    Matsuoka Y; Matsuda Y; Arai H; Sugimoto M
    Urol Case Rep; 2020 Nov; 33():101304. PubMed ID: 33102007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Open mini-flank partial nephrectomy: an essential contemporary operation.
    Russo P; Mano R
    Korean J Urol; 2014 Sep; 55(9):557-67. PubMed ID: 25237456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radical or simple nephrectomy in localized renal cell carcinoma: what is a choice?
    Shulyak A; Banyra O
    Cent European J Urol; 2011; 64(3):152-5. PubMed ID: 24578883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a novel interferon-α2b gene construct with a repetitive hypoxia-inducible factor binding site and its suppressive effects on human renal cell carcinoma cell lines in vitro.
    Fukui N; Kageyama Y; Higashi Y; Kihara K; Kizaka-Kondoh S; Hiraoka M; Shinojima T; Suzuki K; Oya M
    Int J Clin Oncol; 2014; 19(3):497-504. PubMed ID: 23739923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncological and renal medical importance of kidney-sparing surgery.
    Russo P
    Nat Rev Urol; 2013 May; 10(5):292-9. PubMed ID: 23459033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and prognostic significance of second primary cancers in renal cell carcinoma.
    Chakraborty S; Tarantolo SR; Batra SK; Hauke RJ
    Am J Clin Oncol; 2013 Apr; 36(2):132-42. PubMed ID: 22441339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcome and prognostic survival factors in patients with advanced renal cell carcinoma treated with very low-dose interleukin-2, interferon-alpha, and tegafur-uracil: a single-institution experience.
    Kobayashi M; Ikeda H; Nukui A; Suzuki K; Sugaya Y; Yuzawa M; Morita T
    Int J Clin Oncol; 2008 Jun; 13(3):257-62. PubMed ID: 18553237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repetitive transarterial chemoembolization (TACE) of liver metastases from renal cell carcinoma: local control and survival results.
    Nabil M; Gruber T; Yakoub D; Ackermann H; Zangos S; Vogl TJ
    Eur Radiol; 2008 Jul; 18(7):1456-63. PubMed ID: 18309493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flank hernia and bulging after open nephrectomy: mesh repair by flank or median approach? Report of a novel technique.
    Zieren J; Menenakos C; Taymoorian K; Müller JM
    Int Urol Nephrol; 2007; 39(4):989-93. PubMed ID: 17333509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spontaneous retroperitoneal hemorrhage caused by segmental arterial mediolysis.
    Phillips CK; Lepor H
    Rev Urol; 2006; 8(1):36-40. PubMed ID: 16985559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-operative embolization for spontaneous rupture of renal cell carcinoma.
    Watanabe S; Hama Y; Kaji T; Kimura F; Kosuda S
    Ulster Med J; 2005 May; 74(1):66-7. PubMed ID: 16022139
    [No Abstract]   [Full Text] [Related]  

  • 14. Evolving immunotherapeutic strategies in bladder and renal cancer.
    Griffiths TR; Mellon JK
    Postgrad Med J; 2004 Jun; 80(944):320-7. PubMed ID: 15192163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should there be a size limit for elective nephron-sparing surgery?
    Krejci KG; Leibovich BC
    Curr Urol Rep; 2003 Feb; 4(1):21-9. PubMed ID: 12537935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of angiogenesis and microvascular invasion in renal cell carcinoma.
    Dekel Y; Koren R; Kugel V; Livne PM; Gal R
    Pathol Oncol Res; 2002; 8(2):129-32. PubMed ID: 12172577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial.
    Atzpodien J; Kirchner H; Illiger HJ; Metzner B; Ukena D; Schott H; Funke PJ; Gramatzki M; Jürgenson S; Wandert T; Patzelt T; Reitz M
    Br J Cancer; 2001 Oct; 85(8):1130-6. PubMed ID: 11710825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors and the role of nephrectomy in metastatic renal cell carcinoma.
    Uygur MC; Usubütün A; Ozen H; Ayhan A; Kendi S
    Int Urol Nephrol; 1998; 30(6):681-7. PubMed ID: 10195860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solitary brain metastasis 13 years after removal of renal adenocarcinoma.
    Ammirati M; Samii M; Skaf G; Sephernia A
    J Neurooncol; 1993 Jan; 15(1):87-90. PubMed ID: 8455067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgeon's role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: an institutional review.
    Kierney PC; van Heerden JA; Segura JW; Weaver AL
    Ann Surg Oncol; 1994 Jul; 1(4):345-52. PubMed ID: 7850534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.